We know that, Empagliflozin (see structure) is a SGLT2 inhibitor which is being investigated in clinical trials for the oral treatment of type 2 diabetes by Boehringer Ingelheim and Eli Lilly and Company. It is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys. SGLT-2 accounts for about 90 percent of glucose reabsorption into the blood. Blocking SGLT-2 causes blood glucose to be eliminated through the urine via the urethra...
Empagliflozin Lowers Blood Pressure | News | Drug Discovery and Development Magazine ....
3 comments:
Great post. I just stumbled upon your blog and wanted to say that I have really enjoyed browsing your blog posts.
math tutor
According to http://www.rxwiki.com/empagliflozin, Empagliflozin has been shown to "reduce blood glucose by inhibiting glucose reabsorption in the kidney, resulting in significant change in HbA1c independently of beta cell function and insulin resistance." It should be helpful for many people.
Thanq both @Hosneara and @Chris for your comments. Chris, u r right apart from being investigated for Anti-diabetic medication, it also lowers the BP...interesting naa....
Post a Comment